C. Bartenhagen

PRDX6 contributes to selenocysteine metabolism and ferroptosis resistance

The paper identifies PRDX6 as an alternative pathway for selenocysteine metabolism that contributes to ferroptosis resistance in cancer cells.

METTL3 drives telomere targeting of TERRA lncRNA through m6A-dependent R-loop formation: a therapeutic target for ALT-positive neuroblastoma

This study shows METTL3 modifies TERRA lncRNA with m6A, promoting R-loop formation that targets TERRA to telomeres, and inhibiting METTL3 disrupts this process in ALT+ neuroblastoma cells.

METTL3/MYCN cooperation drives neural crest differentiation and provides therapeutic vulnerability in neuroblastoma

This study shows METTL3 and MYCN cooperate to maintain undifferentiated neural crest cells in neuroblastoma, and METTL3 inhibition promotes differentiation and chemosensitivity.

Selenocysteine metabolism is a targetable vulnerability in MYCN-amplified cancers

This study identifies LRP8 as a targetable vulnerability in MYCN-amplified neuroblastoma by showing its role in selenocysteine import and resistance to ferroptosis.

RRM2 is a target for synthetic lethal interactions with replication stress checkpoint addiction in high-risk neuroblastoma

This study identifies RRM2 as a therapeutic target in high-risk neuroblastoma, showing that combined RRM2 and CHK1 inhibition synergistically reduces tumor growth.

PPM1D is a neuroblastoma oncogene and therapeutic target in childhood neural tumors.

This study identifies PPM1D as an oncogene and therapeutic target in neuroblastoma by showing its role in p53 inactivation and tumor growth.